NCT06527794 Remote Hypertension Management for Black Patients
| NCT ID | NCT06527794 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Wake Forest University Health Sciences |
| Condition | Uncontrolled Hypertension |
| Study Type | INTERVENTIONAL |
| Enrollment | 864 participants |
| Start Date | 2024-12-13 |
| Primary Completion | 2028-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 864 participants in total. It began in 2024-12-13 with a primary completion date of 2028-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study will compare two approaches for managing hypertension in Black patients with uncontrolled blood pressure (BP). One approach will include home BP telemonitoring supported by a pharmacist and a community health worker. The other approach will include usual clinic-based care along with a home BP monitor and routine care.
Eligibility Criteria
Inclusion Criteria: * Black or African American race * Hypertension diagnosis * aged 21 to 85 years * Uncontrolled blood pressure as defined by \[a\] most recent SBP ≥140 mmHg and an additional SBP≥140 mmHg within the past 12 months in an outpatient setting (excluding urgent care, emergency department or surgery clinic), or \[b\] most recent SBP\>160mmHg in an outpatient setting (excluding urgent care, emergency department or surgery clinic), or \[c\] referral by PCP for uncontrolled hypertension with at least one documented SBP≥140 mmHg (in clinic or at home) in the past 12 months; and (v) primary care provided at a participating clinic. * Able to speak English * Primary care provided at a participating clinic Exclusion Criteria: * currently pregnant or planning to get pregnant during the study period * residence in a long-term care facility, hospice or with a terminal illness with less than 1 year life expectancy as determined by the Primary Care Physician or study team. Stable chronic illness such as compensated cirrhosis, chronic obstructive pulmonary disease, congestive heart failure etc. will not be excluded. * estimated Glomerular Filtration Rate (eGFR) \<30 ml/min or on dialysis. Patients with a functioning kidney transplant will not be excluded. * inability to provide informed consent or participate in study procedures. For example, conditions that limit ability to participate in phone visits or check BPs in at least one arm. * currently participating in another BP management program. * plan to move out of the area within the next 12 months. * Hispanic ethnicity.
Contact & Investigator
Yhenneko J. Taylor, PhD
PRINCIPAL INVESTIGATOR
Wake Forest University Health Sciences
Frequently Asked Questions
Who can join the NCT06527794 clinical trial?
This trial is open to participants of all sexes, aged 21 Years or older, up to 85 Years, studying Uncontrolled Hypertension. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06527794 currently recruiting?
Yes, NCT06527794 is actively recruiting participants. Contact the research team at Yhenneko.Taylor@advocatehealth.org for enrollment information.
Where is the NCT06527794 trial being conducted?
This trial is being conducted at Winston-Salem, United States.
Who is sponsoring the NCT06527794 clinical trial?
NCT06527794 is sponsored by Wake Forest University Health Sciences. The principal investigator is Yhenneko J. Taylor, PhD at Wake Forest University Health Sciences. The trial plans to enroll 864 participants.